Get the Stockscreener App
22.79
4.21%
0.92
Pre-market:
23.72
0.93
+4.08%
Dbv Technologies Adr stock is traded at $22.79, with a volume of 173.75K.
It is up +4.21% in the last 24 hours and down -2.65% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$21.87
Open:
$21.96
24h Volume:
173.75K
Relative Volume:
0.36
Market Cap:
$1.25B
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-21.70
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+2.52%
1M Performance:
-2.65%
6M Performance:
+147.18%
1Y Performance:
+430.00%
1-Day Range:
$21.52
$22.80
1-Week Range:
$20.49
$23.47
52-Week Range:
$3.91
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
22.79 | 1.20B | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Guggenheim | Buy |
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies to Participate in Upcoming March Investor Conferences - markets.businessinsider.com
Biotech DBV Technologies lines up back-to-back March investor events - Stock Titan
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 - ChartMill
DBV Technologies stock surges on new peanut patch trial data - Investing.com
Phase 3 VITESSE data highlighted by DBV Technologies (NASDAQ: DBVT) - Stock Titan
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies Highlights Additional Data from Successful - GlobeNewswire
DBV Technologies (DBVT) Projected to Post Earnings on Thursday - Defense World
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
DBV Technologies launches $150M ATM offering - MSN
BioImpact LLC reports 9.99% DBV Technologies (DBVT) stake via shares and warrants - Stock Titan
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - MSN
DBV Technologies to Participate in Biotech Summit - Intellectia AI
DBV Technologies to Present VIASKIN® Data at AAAAI 2026 - Intellectia AI
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies S.A. - Via Ritzau
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit - markets.businessinsider.com
Biotech summit to feature DBV Technologies CEO fireside chat - Stock Titan
DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
European ADRs Slip As Winners And Losers Split By Region - Finimize
European ADRs Inched Higher As GSK And Telefonica Jumped - Finimize
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN) - The Globe and Mail
DBV Technologies (NASDAQ:DBVT) Stock Price Passes Above 50 Day Moving Average – What’s Next? - Defense World
European ADRs Started The Week Higher In US Trading - Finimize
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing - Sahm
DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy? - Defense World
European ADRs Slipped, But Biotech Names Still Stole The Show - Finimize
DBV Technologies Announces €166.7 Million in Gross Proceeds - GlobeNewswire
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025 - GlobeNewswire Inc.
Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday - Benzinga
DBV Technologies stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - MSN
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Sahm
The Insider Report: A Tape Fitting for the Holiday - Sahm
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):